EyePoint stock: buy or sell?

EYPT stock price: $1.38 -2.82% At close on November 15th, 2019

Updated on:
November 15th, 2019

0

Shares of EyePoint Pharmaceuticals dropped a terrible -2.82% and closed at $1.38. On Monday EYPT plunged a dreadful -13.28%. On Wednesday EYPT skyrocketed an extraordinary 8.16%.

Should I buy EyePoint stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, EyePoint Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is EyePoint Pharmaceuticals stock a buy?

Financial institutions and banks publish stock ratings everyday. At Stocks2.com, we detected 3 ratings published for EYPT stock in the last month.

Is EYPT a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-25HC Wainwrightn/aBuy
2019-9-24B. Rileyn/aBuy
2019-9-12Guggenheimn/aBuy

EyePoint stock analysis

Daily outlook

EyePoint ended yesterday at $1.38 and dropped a terrible -2.82%.

Shares of EyePoint Pharmaceuticals dropped a terrible -2.82% and closed at $1.38. Since price and SMA200d lines crossed down on Nov/7, EYPT fell $-0.93 per share (-40.26%). For the last 39 days when SMA50d and SMA100d crossed up, EYPT price slipped $-0.79 per share (-36.41%).

EYPT stock chart (daily)

Weekly outlook

EyePoint Pharmaceuticals shares plunged -4.83% this week, ending at $1.38. Late October EYPT rocketed an outstanding 7.17% in just one week.

EyePoint Pharmaceuticals stock fell under the support line what triggered further losses. Possible next supports for EYPT stock are 1.26. Since last week, when EYPT stock price broke down the 40-weeks moving avarage line, it slid $-0.99 per share (-41.77%). Stocks below the 200d moving average line are usually not recommended for average traders.

EYPT stock chart (weekly)

EyePoint stock price history

EyePoint IPO was on January 27th, 2005 at $42.00 per share1. Since then, EYPT stock lost a -96.70%, with a yearly average of -6.90%.

1: Adjusted price after possible price splits or reverse-splits.

EyePoint stock historical price chart

EYPT stock reached 52-week highs on February at $2.82, and all-time highs 2005-01-27 with a price of 48.56.

EyePoint stock price target is $4.20

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 3 price predictions for EYPT stock:
EYPT stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-25HC WainwrightReiteratesn/a$4.50-
2019-9-24B. RileyLowers Target$5.75$4.00-30.4%
2019-9-12GuggenheimInitiatesn/a$4.00-
(in average)$5.80$4.20-28.0%
Moving in a range from $4.50 and $4.00, the price prediction for EYPT stock is $4.20. In average, analysts' outlook on EYPT price target is negative, downsizing the target by a -28.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, EyePoint missed the forecasts of the analysts and posted a fatal EPS of $-0.12 per share when experts were expecting $-0.14.
EYPT earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/an/an/a
2017-Q2-n/an/an/a
2017-Q3-n/an/an/a
2017-Q42018-02-07-0.15-0.13n/a
2018-Q12018-05-08-0.13-0.15n/a
2018-Q22018-09-12-0.09-0.19n/a
2018-Q32018-11-06-0.13-0.19n/a
2018-Q42019-03-14-0.14-0.12n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to 2017, last anual revenues report draw a scary loss of -60.72% to $2.96 million USD. When comparing 2018 vs 2017, likewise, profit margin (that is, the net income divided by revenues) plunged a -1,550.52% to -1,795.71%.

To have an up to date picture of the financial situation of EyePoint Pharmaceuticals, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2018 fiscal year results. Annual EyePoint Pharmaceuticals TTM sales up to December 2018 were $4.57 and income was $-86.13 M USD. When comparing this TTM figures with the last reported annuality, we can review EyePoint business evolution since June 2018: Annual revenues up to December, compared to lastest yearly report, climbed an amazing 54.37%. In contrast, profit margin (net income/sales) plummed at -1,795.71%.

EYPT annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$2.14 M-$-11.90 M-556.1%-
2014$3.47 M62.15%$-13.36 M-385.0%12.27%
2015$27 M665.56%$6.35 M23.9%-147.51%
2016$1.62 M-93.90%$-21.55 M-1330.1%-439.48%
2017$7.54 M365.37%$-18.49 M-245.2%-14.21%
2018$2.96 M-60.72%$-53.17 M-1795.7%187.64%
TTM $4.57 M54.37%$-86.13 M-1884.2%61.98%

Quarterly financial results

EyePoint Pharmaceuticals posted $2.44 M in revenues for 2018-Q4, a 402.47% improvement compared to previous quarter. Reported quarter earnings marked $-11.59 M with a profit margin of -474.77%. Profit margin climbed a 6,341.27% compared to previous quarter when profit margin was -6,816.05%. When comparing turnover to same quarter last year, EyePoint sales marked an astounding increase and skyrocketed a 161.74%.
EYPT quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$0.59 M-$-5.14 M-871.2%-
2017-Q2$0.70 M18.81%$-6.12 M-873.0%19.07%
2017-Q3$0.39 M-45.08%$-5.98 M-1554.0%-2.24%
2017-Q4$0.93 M142.34%$-5.78 M-619.7%-3.36%
2018-Q1$0.93 M-0.54%$-6.98 M-751.9%20.68%
2018-Q2$0.72 M-22.95%$-34.43 M-4815.1%393.38%
2018-Q3$0.49 M-32.03%$-33.13 M-6816.0%-3.78%
2018-Q4$2.44 M402.47%$-11.59 M-474.8%-65.00%

EyePoint ownership

When you are planning to buy shares of a company, it's always worth to review its ownership structure.

EyePoint shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 5.50% of all shares.

In case of EyePoint stock, 55.84% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for EYPT stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related companies:

EYPT
Market cap$149.2 M
Total shares108.1 M
Float shares59.5 M
  - Institutional holdings (%)55.8%
  - Insider holdings (%)5.5%
Shares in short selling0.0%

EyePoint summary

Friday, November 15th, 2019
Open$1.43
Close$1.38
Day range$1.35 - $1.45
Previous close$1.42
Session gain-2.82%
Average true range$0.21
50d mov avg$1.98
100d mov avg$1.72
200d mov avg$1.85
Daily patternlt03a
Weekly pattern lt06c

EyePoint performance

To measure stock performance is always good to benchmark with competitors or related stocks. We compared EyePoint against in the following table:
Stock3m6m12m
EYPTEyePoint Pharmace...-5.48%-25.41%-36.41%

EyePoint competitors

Unfortunately, we could not find any public company that could be defined as EyePoint Pharmaceuticals competitor. This doesn't mean EyePoint Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.